E. Plested

J. Bray, A. Pollard, P. Aley, 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model

A. Simmons, A. Pollard, B. Angus, 2020, PLoS neglected tropical diseases.

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

P. Klenerman, A. Winston, E. Barnes, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing.

N. Andrews, D. Goldblatt, M. Snape, 2020, Vaccine.

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination

A. Pollard, Omar Omar, M. Snape, 2013, Archives of Disease in Childhood.

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

V. Libri, G. Screaton, J. Nguyen-Van-Tam, 2021, The Lancet.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Nguyen H. Tran, Andreas C. Themistocleous, David J. Smith, 2020, Lancet.

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Scott M Elliott, J. Haughney, V. Libri, 2021, The Lancet.

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

J. Vekemans, P. Aley, M. Voysey, 2021, Nature Medicine.

Factors influencing participation in controlled human infection models: a pooled analysis from six enteric fever studies [version 1; peer review: 3 approved with reservations]

A. Pollard, B. Oguti, E. Plested, 2020 .

Factors influencing participation in controlled human infection models: a pooled analysis from six enteric fever studies

A. Pollard, B. Oguti, E. Plested, 2019, Wellcome Open Research.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

D. Bonsall, V. Libri, J. Vekemans, 2021, The Lancet.

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

J. Haughney, V. Libri, M. Kamal, 2022, The Lancet Infectious Diseases.

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

V. Libri, S. Royal, J. Nguyen-Van-Tam, 2021, The Lancet.

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

V. Libri, S. Royal, G. Screaton, 2022, The Lancet Respiratory Medicine.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

J. Todd, P. Simmonds, C. Fraser, 2021, Nature Communications.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

D. Bonsall, V. Libri, J. Vekemans, 2021 .

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

P. Klenerman, A. Winston, G. Screaton, 2021, The Lancet HIV.

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, M. Wand, 2021, Nature Medicine.

Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021

C. Murray, S. Oddie, P. Aley, 2022, Archives of Disease in Childhood.

Streptococcus pneumoniae Carriage Prevalence in Nepal: Evaluation of a Method for Delayed Transport of Samples from Remote Regions and Implications for Vaccine Implementation

D. Murdoch, D. Kelly, Ly-Mee Yu, 2014, PloS one.

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

G. Screaton, P. Aley, B. Angus, 2021, SSRN Electronic Journal.

Investigating a vaccine against COVID-19

E. Plested, 2020, http://isrctn.com/.

Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.

E. L. Miller, P. Aley, N. Andrews, 2023, Vaccine.

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

A. Pollard, P. Aley, M. Voysey, 2023, Clinical and experimental immunology.

‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents

S. Faust, P. Aley, A. Finn, 2020, BMJ Open.

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, P. Klenerman, T. Wrin, 2021, Nature Medicine.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

P. Klenerman, A. Winston, A. Goodman, 2021, SSRN Electronic Journal.

Nasopharyngeal Carriage of Pneumococcus in Children in England up to 10 Years After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Persistence of Serotypes 3 and 19A and Emergence of 7C

J. Hinds, K. Gould, P. Aley, 2022, The Journal of infectious diseases.

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

V. Libri, J. Nguyen-Van-Tam, S. Faust, 2021, Social Science Research Network.

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

V. Libri, G. Screaton, J. Nguyen-Van-Tam, 2023, Journal of Infection.

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial

J. Nguyen-Van-Tam, P. Aley, M. Snape, 2023, Journal of Infection.

A phase I/II study to determine efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers

A. Pollard, E. Plested, 2020, http://isrctn.com/.